Bile Acid Metabolites in Serum: Intraindividual Variation and Associations with Coronary Heart Disease, Metabolic Syndrome and Diabetes Mellitus by Steiner, Carine et al.
Bile Acid Metabolites in Serum: Intraindividual Variation
and Associations with Coronary Heart Disease, Metabolic
Syndrome and Diabetes Mellitus
Carine Steiner
1,2, Alaa Othman
1,2,3, Christoph H. Saely
4,5,6, Philipp Rein
4,5,6, Heinz Drexel
4,5,6,7, Arnold
von Eckardstein
1,2,3*
., Katharina M. Rentsch
1,3.
1Institute for Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland, 2Competence Center for Systems Physiology and Metabolic Diseases, ETH Zurich and
University of Zurich, Zurich, Switzerland, 3Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland, 4Vorarlberg Institute for Vascular
Investigation and Treatment (VIVIT), Feldkirch, Austria, 5Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria, 6Private
University of the Principality of Liechtenstein, Triesen, Liechtenstein, 7Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
Abstract
Bile acids (BAs) regulate glucose and lipid metabolism. In longitudinal and case-control-studies, we investigated the diurnal
variation of serum concentrations of the 15 major BAs as well as the biosynthetic precursor 7a-hydroxy-4-cholesten-3-one
(C4) and their associations, respectively, with coronary artery disease (CAD), diabetes mellitus type 2 (T2DM), and non-
diabetic metabolic syndrome (MetS). In hourly taken blood samples of four healthy probands, the intraindividual 24 h
variation of C4, conjugated and unconjugated BAs ranged from 42% to 72%, from 23% to 91%, and from 49% to 90%,
respectively. Conjugated BA concentrations mainly increased following food intake. Serum levels of C4 and unconjugated
BAs changed with daytime with maxima varying interindividually between 20h00 and 1h00 and between 3h00 and 8h00,
respectively. Comparisons of data from 75 CAD patients with 75 CAD-free controls revealed no statistically significant
association of CAD with BAs or C4. Comparisons of data from 50 controls free of T2DM or MetS, 50 MetS patients, and 50
T2DM patients revealed significantly increased fasting serum levels of C4 in patients with MetS and T2DM. Multiple
regression analysis revealed body mass index (BMI) and plasma levels of triglycerides (TG) as independent determinants of
C4 levels. Upon multivariate and principle component analyses the association of C4 with T2DM and/or MetS was not
independent of or superior to the canonical MetS components. In conclusion, despite large intra- and interindividual
variation, serum levels of C4,are significantly increased in patients with MetS and T2DM but confounded with BMI and TG.
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Introduction
The metabolic syndrome (MetS) is defined as a clustering of
metabolic risk factors for cardiovascular disease including abdom-
inal obesity, elevated blood pressure, impaired fasting glucose (IFG)
or overt diabetes mellitus type 2 (T2DM), hypertriglyceridemia and
low high density lipoprotein cholesterol (HDL-C) levels [1,2,3,4]. In
addition to these canonical components, patients with MetS
frequently present with several additional homoeostatic disturbanc-
es in the regulation of metabolism, inflammation and coagulation, a
state which has been termed metaflammation [5]. The symptoms
and consequences of MetS are as heterogenous as the pathogenic
origin appears to be diverse. Although excess or ectopic fat
deposition and the resulting insulin resistance are considered as
pivotal pathomechanisms, it is important to note additional possible
pathogenic pathways. For example, disturbances in the intestinal
microflora [6] and bile acid (BA) metabolism [7,8] have been
associated with MetS and T2DM.
The BA pool is constituted of primary BAs, which are
synthesized in the liver by the classical and the alternative
pathways, each involving a variety of different enzymes [9], as
well as of secondary BAs, which are generated by deconjugation
and/or dehydroxylation of primary BAs by intestinal bacteria.
7a-hydroxy-4-cholesten-3-one (C4) is a relatively sTable inter-
mediate metabolite in the classical pathway of BA biosynthesis
and is considered to be a plasma biomarker of BA synthesis [10].
Most human BAs are either conjugated to an amino acid, namely
glycine (G) or taurine (T), or unconjugated. Primary BAs
include cholic acid (CA) and chenodeoxycholic acid (CDCA)
as well as their glycine- and taurine-conjugates (GCA, GCDCA,
TCA, and TCDCA, respectively). Secondary BAs comprise
deoxycholic acid (DCA), lithocholic acid (LCA) and ursodeoxy-
cholic acid (UDCA) as well as their glycine- and taurine-
conjugates (GDCA, GLCA, GUDCA, TDCA, TLCA, and
TUDCA, respectively). After biliary secretion and intestinal
deconjugation and/or dehydroxylation, BAs are extensively
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be secreted again in the bile, thereby completing the enterohe-
patic circulation [11].
In the last decade, BAs were discovered to be natural ligands of
the nuclear transcription factor farnesoid X receptor (FXR)
[12,13,14]. In addition to their traditionally recognized role in
cholesterol elimination and emulsification of dietary fat, BAs exert
regulatory effects on their own biosynthesis but also on glucose and
lipid metabolism via activation of FXR. The link between BAs and
lipid metabolism was observed already in the 1970’s when
dyslipidemic patients treated with BA sequestrating resins, such
as cholestyramine, were observed to present not only with
decreased low density lipoprotein cholesterol (LDL-C) but also
with increased plasma levels of triglycerides (TG) and HDL-C
[15,16,17].
In vitro, BAs inhibit the production of very low density
lipoproteins (VLDL) by cultured rat and human hepatocytes in a
dose-dependent and BA species-dependant manner [18,19].
Moreover, FXR knock-out (Fxr
2/2) mice display elevated plasma
levels of VLDL, low density lipoprotein (LDL) [20], and HDL-C
[21]. Conversely, treatment of wild-type mice with a specific FXR
agonist decreased plasma cholesterol levels. Underlying mecha-
nisms include the repression of the transcription factor sterol
regulatory element-binding protein 1c (SREBP-1c) and its
lipogenic target genes [22,23], as well as increased hepatic
expression of receptors involved in lipoprotein clearance (VLDL
receptor [24] and syndecan-1 [25]) and increased apoC-II levels
(co-activates lipoprotein lipase) [26]. Taken together, these data
suggest that FXR activation decreases plasma levels of all
lipoprotein fractions. The effect of FXR activation on atheroscle-
rosis is currently controversial. Despite their pro-atherogenic
lipoprotein profile [20], Fxr
2/2 mice inconsistently presented with
either increased or decreased atherosclerosis in different studies
[27,28,29].
FXR also regulates gluconeogenesis, glycogen synthesis and
insulin sensitivity. For example, hepatic glycogen levels were
found to be increased in diabetic mice after FXR activation [30]
and reduced in Fxr
2/2 mice [31]. In addition, activation or over-
expression of FXR improved glucose tolerance and insulin
sensitivity of diabetic mice [30,32], whereas Fxr
2/2 mice showed
peripheral insulin resistance and impaired glucose tolerance
compared to wild-type mice [30,32,33]. These euglycemic
effects of FXR activation are thought to be at least partly due
to the repression of hepatic gluconeogenic genes (phosphoenol-
pyruvate carboxykinase (PEPCK) and glucose-6-phosphatase
(G6Pase)) [30,32]. However, in contrast to studies with
diabetic mice, treatment of wild-type mice with FXR agonists
has yielded inconsistent results on PEPCK activity or glucose
levels [30,33,34,35,36]. Several studies have shown that the BA
pattern is changed in experimental diabetic rats, with the CA
pool being increased and the CDCA pool being decreased
[37,38,39,40].
The few and small studies characterizing the BA profile in
patients with T2DM have yielded inconsistent results [41,42,43].
In this case-control study we explored whether coronary artery
disease (CAD) or MetS and components thereof including T2DM
are associated with different plasma concentrations of distinct BA
species or of the BA precursor C4.
Due to the observation of a high interindividual variability, and
because C4 and the BAs themselves are known to undergo diurnal
variation in both rodents [44] and humans [45,46], we studied the
influence of daytime and prandial status on the serum concentra-
tions of the 15 major human BAs as well as C4 in 4 healthy
volunteers during 24 hours at 1 hour intervals.
Materials and Methods
Longitudinal study on intraindividual variation
Four healthy volunteers (2 males and 2 females) aged between
27 and 29 years with normal routine liver function tests were
recruited from the staff of our institute to study BAs and C4
profiles over 24 hours. The study protocol was approved by the
local ethics committee and written informed consent was
obtained from all volunteers. An indwelling venous catheter
was placed in the forearm of each subject. The first blood sample
was drawn at 13h00 after all participants had taken an identical
breakfast at 09h15 and an identical lunch at 11h30. During the
overnight study, the participants had an identical supper and
breakfast at 20h15 and 08h45, respectively. For practical reasons,
blood from subject A was always drawn at the exact clock hour
(xxh00), whereas blood from subject B, C and D was drawn with
10 min, 20 min and 30 min delay respectively compared to
subject A. Starting at 13h00, 14 ml blood were drawn from each
subject with 1 hour intervals during 24 hours. Serum was
prepared by centrifugation of the whole blood at 3000 rpm for
10 min at 25uC after having allowed it to clot for at least
30 minutes. 500 ml serum aliquots were immediately frozen at
220uC until analysis.
Case-control-study on association of BAs and C4 with
CAD, T2DM and MetS
The study was approved by the Ethics Committee of the
University of Innsbruck and all participants gave written informed
consent. Six sex- and age-matched patient samples, each encom-
passing 25 patients were selected from a previously described cohort
of consecutive patients undergoing coronary angiography for the
evaluation of established or suspected sTable CAD [47]. The six
patient groups differed by the presence or absence of CAD,
nondiabetic MetS or T2DM: 1. CAD:no/MetS:no/T2DM:no; 2.
CAD:yes/MetS:no/T2DM:no;3.CAD:no/MetS:yes;4.CAD:yes/
MetS:yes; 5. CAD:no/T2DM:yes; 6. CAD:yes/T2DM:yes. In the
CAD classification, the control group comprised cohorts 1+3+5
whereas the CAD patients group comprised cohorts 2+4+6. For the
MetS/T2DM classification, the controls, the MetS patients and the
T2DM patients comprised cohorts 1+2, 3+4, and 5+6 respectively.
One patient from control cohort 1 (CAD:no/MetS:no/T2DM:no)
presented with extremely high serum levels of BAs because of liver
cirrhosis. Therefore his data were excluded from the statistical data
analysis. No other patient presented with clinical manifestations of
liver or bile duct diseases. However, asymptomatic liver disease
cannot be ruled out since no abdominal ultrasound examination
was performed. Liver enzyme acitivities were normal except for
mildly elevated alkaline phosphatase activities in four patients who
presented with 135 U/L, 139 UL, 183 U/L, or 212 U/L (upper
reference range 129 U/L). None of the patients was treated with
bile acid sequestrants.
According to NCEP-ATPIII guidelines, the MetS in individuals
of cohorts 3 and 4 was diagnosed if three or more of the five
following stigmata were present: waist circumference .102 cm in
men and .88 cm in women, TG $1.7 mmol/l (150 mg/dl),
HDL-C ,1.0 mmol/l (40 mg/dl) in men and ,1.3 mmol/l
(50 mg/dl) in women, blood pressure $130/$85 mmHg, and
fasting glucose $6.1 mmol/l (110 mg/dl) but ,7 mmol/L.
T2DM in cohorts 5 and 6 was diagnosed by either fasting glucose
levels $7 mmol/l (126 mg/dl), or plasma glucose levels
$11.1 mmol/l (200 mg/dl) two hours after an oral bolus of
75 g glucose (i.e. 2 h OGTT) or previously diagnosed T2DM.
‘‘Metabolic controls’’ (cohorts 1+2) were defined by the absence of
both MetS and T2DM.
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technique. The angiograms were recorded in multiple projections
with a biplanar digital cardiac imaging system (Philips Integris
DCI). Cine angiograms were reviewed by experienced cardiolo-
gists who were blinded to DXA results. Stenoses were identified,
and the percentage of lumen diameter stenoses was assessed by
visual analysis. Significant CAD was diagnosed by the presence of
significant coronary stenoses with lumen narrowing of at least 50%
(cohorts 2, 4 and 6). In addition, the severity of CAD was
quantified as the sum of all stenoses percentages of a given patient
divided by the number of coronary stenoses in this patient. The
extent was calculated as the number of significant coronary
stenosis with lumen narrowing $50% in a given patient.
Venous blood samples were collected in the morning between
8h00 and 10h00 after an overnight fast of 12 hours and before
angiography. Serum samples for BAs and C4 measurements were
stored at 280uC.
Analytical methods
All laboratory measurements except for BAs and C4 were
performed on freshly isolated serum or plasma samples or full
blood for glycated hemoglobin (HbA1c) in the central laboratory
of the VIVIT study in Feldkirch (Austria). Serum levels of TG,
total cholesterol, LDL-C and HDL-C were determined using
enzymatic assays and precipitation techniques (TG: GPO-PAP,
cholesterol: CHOD/PAP, LDL-C: QuantolipLDL, HDL-C:
QuantolipHDL; all Roche, Basel, Switzerland) on a Hitachi-
Analyzer 717 or 911. HbA1c was determined by high-perfor-
mance liquid chromatography on a Menarini-Arkray KDK HA
8140 (Arkray KDK, Kyoto, Japan), and glucose levels were
measured enzymatically from venous fluoride plasma by the
hexokinase method (Roche, Basel, Switzerland) on a Hitachi 717
or 911. Insulin levels were determined by using an enzyme
immunoassay on an AIA 1200 (Tosoh, Tokyo, Japan). The
HOMA-insulin resistance index (HOMA-IR) was calculated
according to Matthews et al. [48].
The 15 major human BAs (CA, CDCA, DCA, LCA, UDCA as
well as their glycine- and taurine-conjugates) and the BA precursor
C4 were quantified in two 100 ml-aliquots of serum using liquid
chromatography-tandem mass spectrometry as previously devel-
oped by our group [49]. The limits of quantification (LOQ)
ranged from 0.002 to 0.05 mmol/L for the different BAs and was
0.005 mmol/L for C4. Interassay imprecision and inaccuracy were
both below 15% for every BA species and C4.
Statistics
Statistical analyses were performed using IBMH SPSSH
Statistics, version 19 (IBM Corporation, Somers NY, USA) and
SIMCA-P+H 12.0.1.0 (Umetrics Inc., Umea ˚, Sweden). Values
below LOQ were also included into the different statistical
analyses.
Because data on BAs and C4 did not follow a Gaussian
frequency distribution, univariate statistics were performed using
the non-parametric Mann-Whitney and Kruskal-Wallis tests. A
Bonferroni correction was used to compensate for multiple
comparisons. Results were considered to be statistically significant
when the p-value was below a threshold obtained by dividing 0.05
by the number of statistical tests per experiment, which
corresponds to an a of 0.05. Correlations of BA parameters with
each other and other continuous variables were calculated by
using the Spearman rank test.
For multivariate and multiple regression analyses, data which
did not follow a normal distribution were transformed into base 10
logarithms in order to obtain a frequency distribution close to
Gaussian whenever possible. A multiple regression analysis with
forward stepwise selection was used to identify independent
contributors of MetS and T2DM components to BAs or C4
levels. Logistic regression with forward stepwise and backward
stepwise selection was used to find any contributions of BAs or C4
to the classification into healthy or diseased adjusting for the
commonly used biomarkers for MetS and T2DM as well as to
calculate odds ratios.
An orthogonal partial least square-discriminant analysis (OPLS-
DA) was used to estimate the importance of the individual
variables as discriminating biomarkers. OPLS-DA was fitted in
order for the classes to get the highest Q
2 value. The confidence
levels for the model parameters were set to 95% and the
significance levels for DModX and Hotellings T2 were set to
0.05. Normalization of the distance to the model was achieved
using standard deviation units. The SIMCA-P+H 12.0.1.0
program performed cross-validation with 7 groups as a default.
CV-ANOVA (significance of Q2YCV using the F-distribution)
was performed for the models as well as misclassification Tables
and Fisher’s probability. Data for diabetes medication as well as
age and gender were not included in the model in order to avoid
bias in the case of medication and because patients were matched
for age and gender. Samples which were beyond the 95%
confidence interval of the normal multivariate distribution
(Hotelling’s T2) were considered as outliers and were left out
from the final model.
Results
Diurnal profiles of BAs and C4
Figure 1 shows representative diurnal profiles of individual
unconjugated (Figure 1a), glycine-conjugated (Figure 1b) and
taurine-conjugated BAs (Figure 1c). Figure 2 shows the summa-
rized data of unconjugated (Figure 2a), conjugated (Figure 2b) and
total BAs (Figure 2c) for the four subjects. Minimum and
maximum concentrations as well as the intraindividual variability
for the four subjects are shown in Table 1. According to mean
values and standard deviations of measurements in 24 hourly
taken blood samples, the intraindividual 24 h variation of
conjugated and unconjugated BAs ranged from 23% to 91%
and from 49% to 90%, respectively.
The profiles of unconjugated BAs differed markedly from the
profiles of the glycine- and taurine-conjugated BAs. In three out of
four subjects, we observed a strong increase of unconjugated BAs
during the night and early morning, which actually seemed to
consist of two different peaks (Figures 1a and 2a). These peaks
were mainly caused by CA, CDCA and DCA which reached
maximal concentrations of about 4.5 mmol/L, 2 mmol/L, and
2 mmol/L, respectively (Figure 1a). In subjects A and B, levels of
CA reached maximal concentrations of 3 mmol/L and 2 mmol/L,
respectively (data not shown). The acrophase lasted from
approximately 01h00 to 08h00 in subjects B and D and from
02h00 to 10h00 in subject A. Subject C however showed a
different profile with a much less intense peak at approximately
21h00 (CDCA and DCA). In order to disclose a potential
dysregulation of the circadian clocks of subject C, cortisol
concentrations in serum were measured and it was found that
all 4 subjects showed expected cortisol profiles with acrophases in
the morning between 06h00 and 11h00 (data not shown).
By contrast to unconjugated BAs, conjugated BA levels seem to
depend strongly on food intake since both lunch and supper were
followed by increases in the concentrations of conjugated BA
(increased concentrations before 15h00 following the meal at
11h30 and between 20h00 and 00h00 following the meal at
Bile Acids in Metabolic Syndrome
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e2500620h15) (Figures 1b and 2b). It is also important to note that all
glycine and taurine conjugated BA species followed the same
rhythm, although with different absolute concentrations. The
increase after breakfast at 08h45 was less clear and the
concentrations had already started to increase at 07h00 before
the meal was taken at 08h45.
Figure 1. Intraindividual variations of individual unconjugated and conjugated bile acids during one day. Shown are diurnal profiles of
individual unconjugated BAs (A), glycine-conjugated BAs (B), and taurine-conjugated BAs (C) concentrations in subject D. Meals are indicated with
arrows. See text for abbreviations.
doi:10.1371/journal.pone.0025006.g001
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e25006Due to fluctuations of unconjugated and conjugated BAs, the
total BA concentrations also vary considerably throughout the day.
Their profile was mainly influenced by conjugated BAs and,
hence, food intake (Figure 2c).
Figure 2D shows the diurnal variation of C4 in the four
volunteers. C4 levels show a similar degree of intraindividual
variation like BA’s ranging between 42% and 72% (Table 1).
Despite considerable differences between the individual profiles,
both diurnal and prandial effects appear to affect C4 levels: The
highest C4- levels were seen between 19h00 and 1h00, the lowest
C4 levels between 5h00 and 7h00 as well as between 16h00 and
18h00. In addition, the data do not rule out a slight postprandial
increase of C4 levels which may explain the moderate acrophase
around noon (Figure 2D).
Case-control studies
In order to simplify the initial analysis and to avoid excessive
multiple testing, the 15 individual BAs were grouped into primary
BAs (sum of CA, CDCA, GCA, GCDCA, TCA and TCDCA)
versus secondary BAs (sum of DCA, LCA, UDCA, GDCA, GLCA,
GUDCA, TDCA, TLCA and TUDCA), unconjugated versus
conjugated BAs, and total BAs (sum of all 15 BAs). The BA
precursor C4 was analyzed individually. In a first step we tested
whether age or gender affects BA or C4 concentrations. Neither the
5 BA groups nor C4 were affected by age or gender, neither in the
healthy cohort 1 (CAD:no/MetS:no/T2DM:no) nor in the entire
cohort of 149 individuals (Table S1 and Table S2). Furthermore,
there wereno differences in levels of the 5 BA groups orC4 between
treated versus untreated patients for statin use, insulin therapy or
combined oral hypoglycemic drugs (Table S2). We therefore
performed further statistical analyses on unadjusted data.
Associations of CAD status with BAs and C4 levels
Table 2 compares the demographic, anthropometric and
clinical data of 75 patients with CAD and 74 controls free of
significant CAD. The two groups differed significantly from each
other only by systolic blood pressure, the prevalence of statin
treatment (35% versus 59%) as well as the severity and extent of
CAD. Table 3 describes the medians and ranges for the 5 BA
groups and C4 in CAD patients and CAD free controls. Mann-
Whitney tests revealed no statistically significant differences in
plasma levels of C4 or grouped BAs between CAD free controls
and CAD patients. This was also true when comparing the data of
the following cohorts: CAD:no/MetS:no/T2DM:no versus
CAD:yes/MetS:no/T2DM:no; CAD:no/MetS:yes versus CA-
D:yes/MetS:yes and CAD:no/T2DM:yes versus CAD:yes/
T2DM:yes. Also post-hoc analyses of individual bile acid species
did not reveal any statistically significant difference between the
Figure 2. Intraindividual and interindividual variations of summarized unconjugated and conjugated bile acids during one day.
Diurnal profiles of summarized unconjugated BAs (A), conjugated BAs (B), total BAs (C) and C4 (D) concentrations in all four subjects. Meals are
indicated with arrows. See text for abbreviations.
doi:10.1371/journal.pone.0025006.g002
Table 1. Intraindividual variability of bile acids and C4.
Analyte ConcMin ConcMax Subject A
Values
,LOQ Subject B
Values
,LOQ Subject C
Values
,LOQ Subject D
Values
,LOQ
CA ,0.020–0.049 0.077–4.48 0.5996149% 1/24 0.3726155% 0/24 0.039651% 5/24 0.8286154% 0/24
UDCA ,0.020 0.048–0.138 0.033689% 10/24 0.0096147% 21/24 0.024669% 11/24 0.0376106% 13/24
CDCA 0.039–0.163 0.641–2.41 0.4896129% 0/24 0.5076105% 0/24 0.322631% 0/24 0.5356120% 0/24
DCA 0.271–0.480 0.770–2.96 0.983663% 0/24 0.628641% 0/24 0.488622% 0/24 0.934654% 0/24
LCA ,0.050–0.281 0.102–0.799 0.434629% 0/24 0.350648% 0/24 0.047651% 14/24 0.234643% 0/24
GCA 0.030–0.162 2.00–2.67 0.726693% 0/24 0.788655% 0/24 0.618692% 0/24 0.733673% 0/24
GUDCA 0.014–0.029 0.186–0.311 0.093683% 0/24 0.077648% 0/24 0.111673% 0/24 0.088648% 0/24
GCDCA 0.150–0.497 3.82–7.42 1.90673% 0/24 2.34647% 0/24 2.25684% 0/24 1.53652% 0/24
GDCA 0.080–0.415 2.01–5.61 1.75677% 0/24 0.879650% 0/24 0.976691% 0/24 0.902663% 0/24
GLCA ,0.050 ,0.050–0.444 0.021622% 24/24 0.164663% 3/24 0.036667% 18/24 0.059672% 11/24
TCA ,0.005–0.015 0.136–0.700 0.1086167% 0/24 0.059653% 0/24 0.168695% 0/24 0.0436157% 2/24
TUDCA ,0.002 0.003–0.031 0.0046105% 8/24 0.001670% 22/24 0.0076104% 5/24 0.0026122% 20/24
TCDCA 0.019–0.033 0.377–2.25 0.3566103% 0/24 0.183658% 0/24 0.563698% 0/24 0.112689% 0/24
TDCA 0.010–0.022 0.161–1.88 0.2356190% 0/24 0.076652% 0/24 0.4326107% 0/24 0.0796116% 0/24
TLCA ,0.005–0.005 0.031–0.069 0.021662% 0/24 0.027650% 0/24 0.015666% 3/24 0.009676% 7/24
C4 ,0.005–0.016 0.038–0.135 0.014672% 5/24 0.058664% 0/24 0.034651% 0/24 0.038642% 0/24
Primary BAs 0.456–1.13 8.23–13.2 4.18662% - 4.25643% - 3.96681% - 3.78654% -
Secondary BAs 0.768–1.41 4.00–9.32 3.57656% - 2.21634% - 2.14670% - 2.34637% -
Unconjugated BAs 0.598–0.940 1.63–8.46 2.54679% - 1.87665% - 0.920623% - 2.57692% -
Conjugated BAs 0.386–1.03 10.2–18.6 5.21685% - 4.59649% - 5.18689% - 3.56662% -
Total BAs 1.22–2.55 12.2–20.7 7.75659% - 6.46638% - 6.10677% - 6.13646% -
Minimal and maximal concentrations and mean6variation coefficient are given for the 15 individual bile acids, C4 and the grouped bile acids for all four subjects.
Concentrations are given in [mmol/L] and intraindividual variability is given as the mean concentration [mmol/L]6CV [%].
doi:10.1371/journal.pone.0025006.t001
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on the associations of BAs and C4 with MetS and T2DM without
further sub-stratification for the presence of absence of CAD.
Associations of MetS or T2DM with BAs and C4 levels
Table 4 compares the demographic, anthropometric and clinical
data of cohorts which had either T2DM (N=50), non-diabetic
MetS (N=50) or were free of either metabolic disorder (N=49). As
expected by the definitions of MetS and T2DM, both diseased
cohorts differed significantly from healthy controls by body mass
index (BMI), waist circumference, systolic blood pressure, HbA1c,
HDL-C, TG, and HOMA-IR index. In addition, T2DM patients
and MetS patients differed from each other by waist circumference,
glucose, HbA1c, HOMA-IR index, TG, total cholesterol, non-
Table 2. Baseline characteristics of the study population according to CAD classification.
CAD free controls CAD patients p-value
a
median (range) median (range) controls vs CAD patients
Number of subjects 74 75 -
Female/Male 44/30 45/30 0.946
Age 60 (52–73) 61 (55–72) 0.494
BMI [kg/m
2] 29.7 (20.9–40.9) 29.0 (19.1–51.8) 0.235
Waist circumference [cm] 105 (75–136) 103 (73–144) 0.834
Systolic pressure [mmHg] 130 (105–180) 135 (110–165) 0.039
Diastolic pressure [mmHg] 80 (60–110) 80 (60–100) 0.923
Glucose [mM] 5.80 (4.22–19.20) 5.77 (4.44–16.43) 0.631
HbA1c [%] 5.9 (4.9–13.6) 5.8 (5.0–10.1) 0.893
Cholesterol [mM] 5.37 (2.59–8.39) 4.77 (1.94–8.44) 0.064
LDL-cholesterol [mM] 3.25 (1.14–6.29) 3.03 (0.67–6.24) 0.167
HDL-cholesterol [mM] 1.30 (0.54–4.35) 1.22 (0.67–2.23) 0.322
Non HDL-cholesterol [mM] 3.79 (1.50–7.02) 3.42 (0.93–6.37) 0.192
TG [mM] 1.69 (0.41–5.91) 1.51 (0.61–5.62) 0.333
AST [U/L] 26 (14–140) 26 (14–61) 0.797
ALT [U/L] 29 (10–136) 28 (15–133) 0.967
Estimated GFR (Mayo quadratic formula) 97 (61–123) 96 (40–119) 0.989
HOMA IR* 3.20 (0.53–47.14) 2.93 (0.21–26.49) 0.478
Smoking (no/yes) 29/45 22/53 0.205
Statins (no/yes) 48/26 31/44 0.004
Oral antidiabetic drugs (no/yes) 62/12 61/14 0.694
Insulin (no/yes) 67/7 67/8 0.807
Severity CAD - 80.0 (42.5–130.0) -
Extent CAD - 2 (1–8) -
aThe Mann-Whitney U test was used to test quantitative variables and the Chi-square test was used to test qualitative variables.
*8 missing values (4 in CAD free controls and 4 in CAD patients).
doi:10.1371/journal.pone.0025006.t002
Table 3. Associations of bile acids and C4 levels with CAD.
CAD free controls CAD patients p-value
a
median (range) [mmol/L] median (range) [mmol/L] controls vs CAD patients
C4 0.047 (0.006–0.260) 0.033 (0.003–0.266) 0.167
Primary bile acids 1.73 (0.154–13.0) 1.44 (0.207–9.27) 0.245
Secondary bile acids 1.33 (0.073–8.93) 1.03 (0.073–5.30) 0.051
Unconjugated bile acids 1.19 (0.112–8.20) 1.02 (0.165–8.26) 0.247
Conjugated bile acids 1.32 (0.115–21.1) 1.16 (0.221–6.50) 0.289
Total bile acids 3.29 (0.227–22.0) 2.53 (0.712–9.40) 0.113
In order to account for multiple comparisons, a Bonferroni-corrected a error of 0.0083 (6 tests) was set as significance threshold for the Mann-Whitney test.
aMann-Whitney U test.
doi:10.1371/journal.pone.0025006.t003
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antidiabetics, and insulin.
Table 5 summarizes the medians and ranges for the 5 BA
groups and C4 in the three subgroups. Only C4 levels showed a
statistically significant difference as reported by the Kruskal Wallis
test, which however was lost after correction for multiple
comparisons (p=0.009; a=0.05 corresponds to p=0.0083).
Separate comparisons of the data from MetS patients and
Table 4. Baseline characteristics of the study population according to MetS and T2DM classification.
MetS and T2DM
free controls MetS patients T2DM patients p-value
a p-value
a p-value
a
median (range) median (range) median (range) controls vs MetS controls vs T2DM MetS vs T2DM
Number of subjects 49 50 50 - - -
Female/Male 29/20 30/20 30/20 0.934 0.934 1.000
Age 61 (55–68) 61 (52–73) 61 (54–72) 0.520 0.836 0.584
BMI [kg/m
2] 27.4 (19.1–42.1) 29.6 (21.8–37.7) 31.2 (20.0–51.8) 0.005 1.33E-04 0.055
Waist circumference [cm] 97 (73–135) 105 (86–128) 110 (83–144) 2.63E-04 1.79E-05 0.046
Systolic pressure [mmHg] 130 (105–165) 135 (110–180) 140 (110–165) 0.019 0.001 0.200
Diastolic pressure [mmHg] 80 (60–100) 85 (65–110) 80 (60–100) 0.042 0.242 0.372
Glucose [mM] 5.38 (4.22–6.27) 5.58 (4.61–6.72) 8.05 (5.16–19.20) 0.069 6.47E-15 8.31E-14
HbA1c [%] 5.6 (4.9–6.1) 5.8 (5.3–6.4) 7.4 (5.9–13.6) 0.010 5.65E-17 1.38E-15
Cholesterol [mM] 5.39 (2.59–7.80) 5.39 (3.13–8.44) 4.48 (1.94–8.31) 0.559 0.026 0.002
LDL-cholesterol [mM] 3.13 (1.48–5.46) 3.56 (1.14–6.24) 2.60 (0.67–6.29) 0.153 0.009 2.55E-04
HDL-cholesterol [mM] 1.53 (0.98–4.35) 1.10 (0.54–2.07) 1.20 (0.67–2.12) 5.00E-09 1.23E-04 0.324
Non HDL-cholesterol [mM] 3.42 (1.50–6.01) 4.22 (2.25–7.02) 2.90 (0.93–6.76) 4.97E-04 0.206 1.41E-04
TG [mM] 1.10 (0.41–5.62) 2.12 (1.07–4.59) 1.65 (0.62–5.91) 1.41E-12 5.88E-05 0.014
AST [U/L] 26 (15–49) 27 (14–140) 25 (14–55) 0.651 0.338 0.190
ALT [U/L] 26 (14–82) 31 (10–136) 29 (12–133) 0.011 0.069 0.539
Estimated GFR (Mayo quadratic
formula)
95 (63–120) 97 (61–123) 97 (40–120) 0.705 0.657 0.937
HOMA IR* 2.11 (0.21–8.96) 2.95 (0.87–26.31) 6.35 (1.11–47.14) 0.002 1.38E-09 1.03E-05
Smoking (no/yes) 16/33 19/31 16/34 0.578 0.945 0.529
Statins (no/yes) 32/17 30/20 17/33 0.585 0.002 0.009
Oral antidiabetic drugs (no/yes) 49/0 49/1 25/25 0.320 1.03E-08 4.46E-08
Insulin (no/yes) 49/0 50/0 35/15 - 3.15E-05 2.66E-05
aThe Mann-Whitney U test was used to test quantitative variables and the Chi-square test was used to test qualitative variables.
*8 missing values (4 in MetS and T2DM free controls, 2 in MetS patients and 2 in T2DM patients).
doi:10.1371/journal.pone.0025006.t004
Table 5. Associations of bile acids and C4 levels with MetS and T2DM.
MetS and T2DM
free controls MetS patients T2DM patients p-value
a p-value
b p-value
b p-value
b
median (range)
[mmol/L]
median (range)
[mmol/L]
median (range)
[mmol/L]
controls vs MetS
vs T2DM
controls vs
MetS
controls vs
T2DM
MetS vs
T2DM
C4 0.029 (0.004–0.146) 0.054 (0.006–0.258) 0.052 (0.003–0.266) 0.009 0.043 0.002* 0.420
Primary bile acids 1.75 (0.154–13.0) 1.29 (0.299–9.56) 1.67 (0.207–9.27) 0.485 0.243 0.711 0.416
Secondary bile acids 1.10 (0.073–8.93) 0.996 (0.241–8.01) 1.33 (0.115–5.30) 0.290 0.834 0.210 0.150
Unconjugated bile acids 0.999 (0.112–8.20) 1.13 (0.287–5.52) 1.28 (0.195–8.26) 0.329 0.429 0.138 0.478
Conjugated bile acids 1.46 (0.115–21.1) 0.928 (0.342–16.4) 1.18 (0.172–6.50) 0.496 0.210 0.716 0.517
Total bile acids 2.85 (0.227–22.0) 2.40 (0.884–17.6) 3.33 (0.831–9.73) 0.409 0.467 0.524 0.188
In order to account for multiple comparisons, a Bonferroni-corrected a error of 0.0083 (6 tests) was set as significance threshold for the Kruskal-Wallis test whereas a
corrected a error of 0.0028 (18 tests) was set as significance threshold for the Mann-Whitney test.
aKruskal-Wallis test.
bMann-Whitney U test.
*indicates a statistically significant difference after Bonferroni correction for multiple testing.
doi:10.1371/journal.pone.0025006.t005
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revealed a statistically significant difference in C4 levels between
controls and T2DM patients, which persisted also after Bonferroni
correction for multiple comparisons (p=0.002; a=0.05 corre-
sponds to p=0.0028). None of the other BA parameters showed
any difference between the three groups. Neither did the post-hoc
analyses of individual bile acids reveal any statistically significant
difference between the three groups.
Because all T2DM patients also fulfilled the definition of MetS,
we also compared the compiled data of these two patient groups (i.e.
T2DM+MetS) withthose of the controls. In this analysis also, serum
levels of C4 differed significantly from those of controls (controls:
median=0.029 mmol/L, range=0.004–0.146 mmol/L; combined
MetS and T2DM: median=0.054 mmol/L, range=0.003–
0.266 mmol/L; p=0.003). No difference was observed between
controls and combined MetS and T2DM patients for any of the
BAs.
Because of previous reports we also tested whether MetS and
T2DM patients differ from controls by the ratio of primary to
secondary BAs [50], the glycine-conjugated BA GCDCA [51] or
the ratio of CA to CDCA [43]. The ratio of primary to secondary
BAs differed significantly between diabetics and controls
(p=0.011), but this statistical significance was lost after correction
for multiple comparisons. When we compared the compiled data
of the MetS and the T2DM group with controls, the ratio
primary/secondary BAs also differed between patients and
controls (p=0.042), but again the statistical significance was lost
after correction for multiple comparisons.
Correlations of C4 and BAs
Table 6 shows the bivariate correlations of C4 and grouped BAs
with each other as well as with biomarkers of MetS or T2DM. C4
plasma levels showed weak but statistically significant correlations
with unconjugated BAs (r=0.199; p=0.015) secondary BAs
(r=0.210; p=0.010) and total BAs (r=0.165; p=0.044). C4
correlated more with some components of the MetS, glucose and
lipid metabolism, namely with BMI (r=0.210; p=0.010), glucose
(r=0.174; p=0.034), HbA1c (r=0.271; p=0.001), HOMA-IR
(r=0.317; p=1.29E-04), TG (r=0.356; p=8.35E-06), non-HDL-
C (r=0.260; p=0.001), total cholesterol (r=0.219; p=0.007) and
LDL-C (r=0.213; p=0.009).
Most of the BAs were highly correlated with each other.
Additional statistically significant correlations were found to exist
between secondary BAs and HbA1c (r=0.166; p=0.043) or TG
(r=0.181; p=0.027), between unconjugated BAs and HbA1c
(r=0.203; p=0.013), TG (r=0.201; p=0.014) or HOMA-IR
(r=0.223; p=0.008) and between total BAs and HbA1c
(r=0.168; p=0.041), TG (r=0.177; p=0.031) or HOMA-IR
(r=0.173; p=0.040). The ratio primary/secondary BAs did not
show any statistically significant correlations with C4, unconju-
gated BAs, conjugated BAs or any of the parameters character-
izing glucose or lipid metabolism.
Because the components of the MetS were also highly
correlated with each other, we performed a multiple linear
regression analysis to unravel independent determinants of C4
levels as well as the role of C4 as an independent determinant of
the other variables. For these tests we included C4, TG, HOMA-
IR, HbA1c, non-HDL-C as well as BMI as either the dependent
or the determinant variables (Table 7). We did not consider waist
circumference, glucose, total or LDL-C because these variables
were redundant and correlated less with C4 than BMI, HbA1c,
and non-HDL-C, respectively. In this multiple regression
analysis, only TG and BMI evolved as significant independent
determinants of C4 (adjusted R
2=0.145; p=7.26E-06). When
BMI was set as the dependent variable, it was significantly
and independently associated with C4 levels as well as with
HOMA-IR (adjusted R
2=0.227; p=7.03E-09). No other MetS
and T2DM parameter was independently determined by C4
(Table 7).
Logistic regression and principal component analysis of
associations between C4 and MetS
Based on the results of the univariate analyses and correlations
described in Tables 3, 5 and 6, logistic regression and principal
component analyses were performed to test whether C4 shows a
statistically independent association with the MetS. To this end we
compared data of MetS and T2DM free controls (N=49) with
combined data from patients with MetS or T2DM (N=100).
Logistic regression analysis was used to determine whether
plasma levels of C4 are associated with MetS and T2DM
independently of those components of the MetS which showed
the highest correlations with C4 (Table 6), namely TG, HbA1c,
HOMA-IR, non-HDL-C and BMI. Upon both forward and
backward stepwise regression analysis, the association of C4 with
MetS/T2DM was lost, whereas TG and HbA1c remained
significantly associated with MetS/T2DM in either model
(classification Table: 87%, Nagelkerke R
2=0.639). These results
indicate that C4 is not independently associated with MetS and
T2DM.
Figure 3 shows the results of the OPLS-DA. After reducing the
dimensions of the data to a single principal component and an
orthogonal component, the two groups showed a clear tendency
for separation, however complete separation was not achieved
(Figure 3a). According to the model evaluation, R
2Y (percent of
the model fitting the data) represented 50% and Q
2Y (goodness
of prediction) represented 43%. The loading plots, which show
the weights of the individual variables within the model and
hence their contribution to the disease state, revealed that TG,
HDL-C (inversely), HOMA-IR, HbA1c, glucose, waist circum-
ference, BMI and systolic blood pressure contributed most
strongly to the model (95% CI.0) (Figure 3c). Among the BA
parameters, C4 was the strongest contributor to the model,
followed by the secondary BA DCA. All other parameters
(including all BAs except DCA) had a 95% CI beyond zero and
therefore they did not significantly contribute to the model. The
variable importance for the projection (VIP) plot shows the
contribution of each variable to the variation in both the X space
and the Y space (hence its correlation with other variables and
the control or disease state). A coefficient value .1 means that
the variable is ‘‘important’’. In our model, the VIP plot showed
that TG, HOMA-IR, HDL-C, HbA1c, glucose and waist
circumference had the highest VIP coefficients (Figure 3d).
BMI, systolic blood pressure, C4 and DCA also contributed to
the model; however their 95% CI extended below 1.0, so that
their contribution to the model must be interpreted with caution.
All other parameters did not significantly contribute to the model
according to the VIP plot.
Another OPLS-DA model was fitted to the data of the 50
T2DM patients versus the 49 controls without MetS and T2DM
(Figure S1). In this case, the separation between the two groups
became clearer although some overlap was still present. R
2Y and
Q
2Y represented 69% and 58% respectively. In the loading plot,
the variables contributing most strongly to the T2DM model were
the same as in the previous model but with HbA1c, glucose and
HOMA-IR coming first as expected. A noteworthy difference in
this model was that C4 contributed more strongly to the model
than did systolic blood pressure.
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This study provides the as yet most comprehensive data on the
diurnal intraindividual variation of serum concentrations of 15 BA
species and their biosynthetic precursor C4 as well as on their
associations with CAD, T2DM, and non-diabetic MetS.
Diurnal variation of BAs and C4
During a 24-hours cycle, all BA species and C4 varied
considerably in their serum concentrations with variation
coefficients between 42% and 72% for C4 and reaching up to
190% for TDCA in subject A (Table 1). In addition, although we
studied only four probands, there is considerable interindividual
variation in both the timing and quantity of peak and trough levels
of BA or C4 in serum (Figure 2). Despite this limitation, we draw
some conclusions on both the physiology behind the intraindivid-
ual variation and the consequences for the clinical or epidemio-
logical validation of BA and C4 as biomarkers.
The reasons for the high degree of intraindividual variation
appear to differ for the various BAs and C4: conjugated BAs
appear to be altered by the prandial state whereas unconjugated
BAs seem to undergo diurnal changes independently of food
intake. The strong prandial effect on total and conjugated BAs was
observed already previously [45,52,53,54], whereas the diurnal
changes of unconjugated BAs independently of food intake have
not yet been described.
We, like other authors [53,54], found that serum levels of
conjugated BAs are strongly influenced by food intake and peak
one to two hours after food intake (Figures 1b and c, Figure 2).
However, since serum levels of conjugated BAs already increased
before breakfast and decrease more slowly in the night after supper
than in the afternoon after lunch we cannot exclude additional
non-prandial effects on serum levels of conjugated BAs. Interest-
ingly in our experiment all ten conjugated BA species were found
to increase in parallel. This is in contrast to other reports where
CDCA and DCA concentrations were described to increase more
rapidly than CA concentrations, possibly due to passive reabsorp-
tion of the dihydroxylated BAs in the proximal intestine as
opposed to active absorption of CA in the ileum [52,53].
Unconjugated BA concentrations increased dramatically during
the night and early morning (Figures 1a and 2a). Since supper was
taken at least 5 hours earlier at 20h15 and since other meals
caused no or much less prominent increases of unconjugated BAs,
this phenomenon appears to reflect diurnal biorhythm rather than
postprandial effects. However, our findings are in contrast to those
of other authors who observed maximal serum concentrations of
unconjugated BAs between breakfast and dinner with little
changes between midnight and breakfast [55]. They suggested
the existence of a pool of unconjugated BAs in the intestine, which
is reabsorbed as a consequence of increased intestinal motility
following breakfast intake. We have no explanation for the
discrepant findings except that the sleep-wake phase may have
been shifted in that study compared to ours. Interestingly, the
maxima in the concentrations of unconjugated BAs observed by us
occur close to the daytime at which BA biosynthesis was previously
found to be maximal, namely at 06h00 or 09h00 [46,56]. It is
hence tempting to hypothesize that the peak serum concentration
of unconjugated BAs reflects peak BA biosynthesis. However, as
discussed before, the unconjugated BAs recovered in the
bloodstream are of intestinal rather than direct hepatic origin.
Moreover, one would expect only the primary BAs CA and
CDCA to be elevated if the peak observed was due to BA
biosynthesis. However DCA levels peaked to the same degree as
did CDCA levels (but less than CA levels). Therefore and because
serum levels of the biosynthetic precursor C4 peaked considerably
earlier (Figure 2d), we consider it as unlikely that the peak of
unconjugated BAs observed during the night reflects increased BA
biosynthesis.
The C4 profile showed two peaks, one between 19h00 and
01h00 and another between 11h00 and 15h00 (Figure 2D). Our
findings are in accordance with those of a previous study in which
also two peaks at 21h00 and 13h00 were observed [45] but only in
partial agreement with another study in which only one peak was
observed at approximately 13h00 [57]. Our observation is also in
accordance with the two studies which measured radiolabelled
CO2 in the breath as a marker of BA biosynthesis. In the classical
pathway of BA biosynthesis, which accounts for the majority the
biosynthesis, the shortening of the side chain and subsequent
release of radiolabelled propionic acid takes place at a relatively
late stage in the pathway [58]. This would explain the several
hours delay between the peak observed for C4 and the peak of
labelled CO2 in the breath.
In conclusion, because of chronotropic and prandial effects,
unconjugated and conjugated BAs as well as C4 show a very high
degree of intraindividual variation, which makes their clinical use
as biomarkers difficult. The need to be consistent regarding blood
sampling time and fasting state was already mentioned in 1980
[59] and this issue is still ongoing since total BAs are commonly
Table 7. Results of the multiple regression analysis showing the standardized coefficients for each determinant variable which
significantly contributed to a given model.
Dependant variables
Determinant variables C4 Triglycerides BMI Non-HDL-C HOMA-IR HbA1c
C4 - n.s. 0.160 n.s. n.s. n.s.
Triglycerides 0.295 - n.s. 0.604 0.134 n.s.
BMI 0.223 n.s. - n.s. 0.321 n.s.
Non-HDL-C n.s. 0.584 n.s. - n.s. 20.145
HOMA-IR n.s. 0.318 0.422 20.184 - 0.502
HbA1c n.s. n.s. n.s. 20.192 0.414 -
Adjusted R-square of model 0.145 0.380 0.227 0.380 0.383 0.284
Significance of model 7.26E-06 1.78E-15 7.03E-09 8.04E-15 5.67E-15 3.53E-11
The variable inclusion criterion was set to p#0.05.
doi:10.1371/journal.pone.0025006.t007
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diseases. Conjugated BA levels can be controlled rather easily by
the use of fasting blood only. However unconjugated BAs and C4
are more difficult to control since their acrophase is early in the
morning and because already the four probands of our study
showed considerable interindividual variations in the time course
of unconjugated BA and C4. For example it is very likely that
many fasting blood samples drawn typically between 08h00 and
10h00 as in our case-control study will contain levels of
unconjugated BAs which have not returned to baseline at the
time of sampling.
Association of BAs and C4 with CAD, T2DM and MetS
In our study none of the BA parameters was associated with
CAD upon univariate statistical analyses, therefore we did not
perform further analyses with the CAD classification. By contrast,
both MetS and T2DM were associated with similarly elevated
plasma levels of C4. This finding appears to be in agreement with
previous studies which reported increased BA synthesis in diabetic
patients, at least before insulin treatment [39–41,60]. Upon
multivariate analysis of our data however, the association of C4
with T2DM and MetS was lost, mainly because of the dependence
of C4 levels of TG and BMI. In the orthogonal partial least
square-discriminant analysis as well, C4 was a weaker contributor
to MetS than its canonical components. We, like others, also could
not detect statistically significant associations of other serum
markers of BA metabolism with T2DM or MetS upon univariate
analyses, including those which were previously associated with
T2DM, namely total CDCA or GCDCA [41,61], primary to
secondary BAs ratio [44] and CA to CDCA ratio [45].
The weaker as well as statistically not independent association of
C4 (and probably the absent associations of BAs) with MetS or
T2DM must be interpreted in the light of the very large
interindividual variation of BAs and C4 serum levels. The
coefficient of variation for C4 within the individual cohorts
ranged from 62% to 99% compared to 33% to 78% for TG,
which otherwise is the most variable component of the MetS. One
important reason for this large variation is the diurnal variation of
C4 and BA levels which we described and discussed before. This
large intraindividual variation translates into even larger interin-
dividual variation because not all participants are synchronized
and it is further increased by additional influencing factors. Serum
levels of BAs are even more strongly influenced by internal factors
than C4, because they undergo an extensive enterohepatic
circulation. Thus the lack of independent association of C4 and
the lack of any statistically significant association of the BAs with
MetS and T2DM does not contradict the pathogenic links
between BA metabolism and MetS or T2DM, for which many
lines of evidence have been produced by animal experiments and
intervention studies in humans [62,63].
Interestingly, C4 showed several positive and statistically
significant correlations with single components of the MetS,
namely BMI, TG, glucose, HbA1c, and HOMA-IR. Some of
these variables also showed statistically significant positive
correlations with other parameters of BA metabolism, namely
secondary, unconjugated and total BAs, but none was as strong as
those with C4, probably also because of the biological reasons
indicated before. Only the positive correlation between C4 and
TG is in agreement with the hypertriglyceridemic effects of BA
sequestration or inborn defects of intestinal BA reabsorption [64].
By contrast, the positive and significant correlations of C4 and the
BAs with non-HDL-C, glucose, HbA1c and HOMA-IR are in
contrast to known regulatory functions of BAs as well as several
previous findings made by intervention studies in men or mice:
BAs activate the nuclear hormone receptor FXR and thereby
repress several lipogenic and gluconeogenic target genes and
hence lower plasma levels of cholesterol, TG and glucose [65].
Most recently BAs were also found to activate the G-protein
coupled receptor TGR5 and thereby exert anti-obesity as well as
insulin sensitizing effects [66]. The cholesterol lowering and
euglycemic effects of treatment with BA sequestrants [7,60], which
causes a compensatory increase of BA synthesis by 40% [60], are
also in opposition with the positive correlations that we observed
for C4. Moreover, plasma concentrations of BA were found
significantly increased in patients with prior gastric bypass surgery
as compared to both overweight and obese controls and to
correlate negatively both with fasting triglycerides and 2 h-post
meal-glucose [67].
A possible explanation for our, at first sight counterintuitive
observations is provided by the results of our multiple regression
analyses.
On the one hand and interestingly, C4 levels were not found to
be an independent determinant of the components of MetS and
T2DM except for BMI suggesting that bile acids may affect body
weight gain. In this regard it is interesting to note, that FXR is
expressed in murine adipocytes where it appears to promote
adipocyte differentiation as well as lipogenesis and to decrease
lipolysis [68]. In agreement with a physiological role of these in
vitro observations, in a mouse model of obesity, FXR deficiency
rather than FXR stimulation attenuated body weight gain and
improved insulin sensitivity by extrahepatic FXR effects [69].
On the other hand and even more importantly, BMI and TG
were identified as independent determinants of C4 serum levels.
This unexpected and as yet unknown direction of multivariate
correlations suggests that the synthesis of BAs is influenced by
triglyceride metabolism and adipose tissue. As yet this direction of
the possibly mutual relationships between BA synthesis and several
components of the MetS has not been much investigated by
experiments. For example, patients with gallstones, which occur at
an increased frequency in patients with MetS, show increased
production of both TG and BAs [70]. Finally, one must consider
the possibility that BA synthesis, triglyceride metabolism and
adipose tissue are not only causally linked with each other but
regulated in parallel by another factor.
Our study has several limitations. The problems of diurnal
variation and the resulting large intra- and interindividual
variations of C4 and BAs have been described and discussed
before. In addition we cannot exclude that the young and healthy
volunteers of our pilot study differ from the older and
metabolically compromised patients of our clinical study in the
Figure 3. OPLS-DA of combined MetS and T2DM patients (N=100) versus MetS and T2DM free controls (N=49). A) Score plots
showing individual measurements (black triangles: controls; white triangles: MetS and T2DM patients). B) Model evaluation: R
2X, R
2Y and Q
2Y
represent the amount of explained X-variation, Y-variation and predicted Y-variation respectively. Cross validation (CV) is evaluated using the CV-
ANOVA p-value, which represents the significance of the predicted Y-variation for the given F value. Correct classification shows the percentage of
values classified correctly for the entire group according to the model and Fisher’s probability represents the likelihood of obtaining the same
classification result by chance. C) Loading column plots with the weights representing the contribution of each variable to the model component
scores. D) Variable importance of the projection (VIP) coefficient plot indicating which variables are important in explaining both the X- and the Y-
data. Error bars show 95% confidence intervals for the calculated weights and importance.
doi:10.1371/journal.pone.0025006.g003
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large interindividual variation in C4 and BA levels, our clinical
study also suffers from a relatively small study size (N=150),
although to the best of our knowledge, it is as yet the largest study
investigating the associations of CAD, T2DM and MetS with BAs
and C4. In addition, basal fasting bile acid levels are low and may
not help to discriminate physiological and pathological bile acid
metabolism between the different patient and control cohorts of
our study. Provocation by standardized test meals or treatment
with bile acid sequestrants as in some other small studies [60,61]
may have helped to identify differences in bile acids. However this
kind of provocation studies needs long term intervention with
standardized meals or bile acid sequestration which are not
feasible in the clinical setting of our study. A third limitation is the
medication of many patients with statins or anti-diabetics which
may influence BA synthesis and metabolism, although we did not
see any statistically significant differences between consumers and
non-consumers of these drugs. Finally, we cannot firmly exclude
the asymptomatic presence of liver or bile duct diseases in our
patients since no ultrasound examinations have been performed.
However, none of the patients presented with strongly elevated
liver enzymes. Therefore and because bile acids are considered as
very sensitive markers of cholestatic liver disease but were in the
normal range in ou patients, we assume that none of the patients
presented with relevant liver or bile duct disease.
In conclusion, despite the considerable intra- and interindivid-
ual variation of BA and C4 serum levels, patients with MetS and
T2DM present with significantly increased plasma levels of C4, a
biomarker of BA synthesis. This association is confounded by
positive correlations of C4 with TG and BMI. These data suggest
that BAs are not only influencing lipid and glucose metabolism as
well as adiposity but also that triglyceride metabolism and adipose
tissue reciprocally influence BA synthesis.
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